Perinatal Mental Health Care Pathway

�This regional care pathway provides�guidance for all Health and Social Care (HSC) professionals who come into contact with pregnant women. In addition, each Trust has developed a local adaptation of this pathway for their population.�

Cervical screening: Frequently asked questions (FAQs)

Testing for high-risk human papillomavirus (HR-HPV) as triage and test of cure was introduced into the Northern Ireland Cervical Screening Programme on Monday 28 January 2013. This policy change will significantly alter the screening pathway for women with a mild dyskaryosis or borderline smear result. The link between HR-HPV infection and the development of cervical cancer has now been clearly established, with almost 100% of cervical cancers containing HPV DNA. Women with no evidence of HR-HPV infection are extremely unlikely to develop cervical cancer in the short to medium term. HPV triage is the process whereby HR-HPV testing is used to manage women with low grade cervical abnormalities. Only 15-20% of women with a borderline or mild smear result have a significant abnormality that needs treatment. HR-HPV testing is effective in identifying which women may need treatment and allows colposcopy resources to be allocated more effectively. The test of cure process is being introduced because it is now known that women with a normal or low grade smear test, and who are HR-HPV negative at six months after treatment, are at very low risk of residual disease. These women do not need to be recalled for another screening appointment for three years. The test of cure process means all post-treatment smears (at six months) that are reported as normal, borderline or mild dyskaryosis will be tested for HR-HPV. Those women who are HR-HPV positive will remain at colposcopy. HR-HPV negative women can be safely returned to recall in three years. It is estimated that the HR-HPV test of cure will allow approximately 80% of women who have been through treatment to avoid undergoing annual smear tests. These FAQs answer the most common and important queries in relation to HPV and the new screening process, and were distributed to all GPs in Northern Ireland. They can be downloaded as a PDF from this website.

Cervical screening programme: HPV triage and test of cure protocol

Testing for high-risk human papillomavirus (HR-HPV) as triage and test of cure was introduced into the Northern Ireland Cervical Screening Programme on Monday 28 January 2013. This policy change will significantly alter the screening pathway for women with a mild dyskaryosis or borderline smear result. The link between HR-HPV infection and the development of cervical cancer has now been clearly established, with almost 100% of cervical cancers containing HPV DNA. Women with no evidence of HR-HPV infection are extremely unlikely to develop cervical cancer in the short to medium term. HPV triage is the process whereby HR-HPV testing is used to manage women with low grade cervical abnormalities. Only 15-20% of women with a borderline or mild smear result have a significant abnormality that needs treatment. HR-HPV testing is effective in identifying which women may need treatment and allows colposcopy resources to be allocated more effectively.The test of cure process is being introduced because it is now known that women with a normal or low grade smear test, and who are HR-HPV negative at six months after treatment, are at very low risk of residual disease. These women do not need to be recalled for another screening appointment for three years.The test of cure process means all post-treatment smears (at six months) that are reported as normal, borderline or mild dyskaryosis will be tested for HR-HPV. Those women who are HR-HPV positive will remain at colposcopy. HR-HPV negative women can be safely returned to recall in three years. It is estimated that the HR-HPV test of cure will allow approximately 80% of women who have been through treatment to avoid undergoing annual smear tests. This flowchart poster outlines the new triage and test of cure process. It was distributed to all GPs in Northern Ireland and is available to download as a PDF from this website.�

Whooping Cough (Pertussis) immunisation - Poster

This poster encourages uptake of the whooping cough vaccine for pregnant women. Cases of whooping cough are on the increase - by getting the vaccine while pregnant you can protect your baby.

Protecting you and your baby: Blood tests at your first antenatal visit

This leaflet gives information on the blood tests that are normally offered and recommended at the first antenatal visit. These tests look for possible health problems that could affect the mother's health and the health of the baby. Only one sample of blood is needed to do all six tests. The tests are done by consent and this leaflet should help pregnant women make their decision.

Public Health Agency Business plan 2013-2014

This Business Plan sets out the key priorities and actions that will be progressed by the Public Health Agency (PHA) in 2013/14. The PHA believes that these actions will have the biggest impact on improving levels of health and social wellbeing, protecting the health of the community, and ensuring patients continue to receive high quality and safe treatment and care services.The business plan is available to download below.

Public Health Agency Business plan 2014-2015

This Business Plan sets out the key priorities and actions that will be progressed by the Public Health Agency (PHA) in 2014/15. The PHA believes that these actions will have the biggest impact on improving levels of health and social wellbeing, protecting the health of the community, and ensuring patients continue to receive high quality and safe treatment and care services.The business plan is available to download below.

Lifeline Consultation Report - A summary of the feedback to the Public Health Agency's public consultation process on the Lifeline Crisis Response Service

This report is a summary of the feedback from the public consultation process on the current Lifeline contract and future options.

New immunisations vaccines 2014

Two new vaccine brands – Infanrix IPV Hiband Boostrix-IPV – are being introduced into the national routine immunisation schedule in 2014, alongside Infanrix IPV and Repevax. This chart shows who they are for and aims to avoid the possibility of confusion between the brands. �

Getting to know your baby

This leaflet is for women who are pregnant and describes how they can start connecting with their baby. It explains what babies need to feel safe and secure and will help new mothers get off to a good start with feeding and caring for their babies.

Ovarian cancer leaflet

This booklet has been reproduced and distributed in Northern Ireland to raise awareness of the signs and symptoms of ovarian cancer among women. Ovarian cancer is often diagnosed at a late stage but the sooner it is detected the easier it is to treat. The original leaflet produced by Target Ovarian Cancer is available in other languages at: www.targetovariancancer.org.uk http://www.targetovariancancer.org.uk/about-ovarian-cancer/what-ovarian-...

Ovarian cancer poster

This poster has been reproduced and distributed in Northern Ireland to raise awareness of the signs and symptoms of ovarian cancer among women. The sooner ovarian cancer is detected the easier it is to treat.�

Northern Ireland cervical screening programme: information for primary care and smear takers

From January 2011, the Northern Ireland cervical screening programme no longer invited women aged under 25 to attend for screening. In addition, the screening interval for women aged 25-49 was reduced to every three years.This�booklet describes the rationale for the change in policy so that primary care staff and smear takers can provide appropriate and accurate advice to patients.

Joint Commissioning Plan of the Health and Social Care Board and the Public Health Agency: 2010-2011

Legislation enacted on 1 April 2009 created a new Commissioning system with the establishment of a region-wide Health and Social Care Board, including 5 Local Commissioning Groups (LCGs), and a Public Health Agency. In line with Departmental direction and guidance the objectives of the new commissioning arrangementswere to:- Approach the future delivery of Health and Social Care from a region-wide perspective focused on outcomes.- Ensure local sensitivity through the creation of five Local Commissioning Groups reflective of their areas.

Public Health Agency Business plan 2010-2011

This second corporate business plan explains the purpose of the PHA and focuses on health improvement, health protection and addressing health inequalities. The business plan is available to download below.